CAR-T cell therapy for relapsed blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new CAR-T cell therapy (called ARI-0001) for people with certain blood cancers that have not responded to standard treatments. The treatment uses your own immune cells to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a type of blood cancer (like some leukemias or lymphomas) that has come back or not responded to treatment.
- Your cancer cells have a marker called CD19.
- You are generally healthy enough to be active (ECOG score 0-2) and your organs (heart, lungs, kidneys, liver) are working well.
- You are not pregnant, not breastfeeding, and agree to use birth control for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
This trial tests a CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatment. The therapy targets specific markers on cancer cells to help your immune system fight the disease.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial uses a patient's own T cells, modified to target a protein called CD19 on cancer cells, to treat B-cell cancers that have come back or not responded to standard treatments. It is for people aged 14 to 70 with certain types of leukemia or lymphoma.
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
This trial tests a new treatment using your own immune cells, called CAR-T cells, that are made from a donor to attack cancer cells in people with B-cell blood cancers that have come back or not responded to standard treatments. The goal is to see if these cells can help people who haven't had success with other therapies.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.